Teva Pharma sent a letter to Myan explaining that they are stronger than ever, both in its generic and specialty businesses.
Article continues below
"We have significantly strengthened the fundamentals of our company, solidified our key franchises, put in place robust engines for growth and provided a clear roadmap to further reinforce our industry-leading position.
"Your repeated statements regarding Teva’s prospects are wholly inaccurate. We are vigorously and successfully protecting our core franchises. Our specialty pipeline is in the best shape it has ever been and we continue to bolster it relentlessly. So are our capabilities in generics. Like product portfolios of many other leading pharmaceutical companies, our portfolio is also changing.
"Value creation and integration of acquired companies. In the last two decades, Teva has transformed the generics space, setting the industry standards for others to follow. In doing that, it generated returns for our stockholders in excess of 1600%, one of the highest rates in the pharmaceutical industry.
"This performance has been achieved through both organic growth and large global and diverse acquisitions that required successful integration of cultures, activities, businesses and assets in numerous territories.
"The unique experience Teva has gained from the more successful (and sometimes also less successful) acquisitions is fully applied in everything we are doing, and we will continue to do so.
"Diversity and globalization. Teva is a truly global, highly diverse company with a unique combination of cultures, geographies and businesses. It starts with its diverse top leadership team and goes all the way throughout the ranks. Israel has a significant role in Teva’s legacy and culture, and it has been contributing substantially to its success.
"At the same time, as in any of the other countries in which it operates, Teva invests in Israel in those activities that create value and enhance competitiveness to the company on a global level," Teva said in the letter. ■